Kidney cancer is
considered to be one of the 10 most common cancers affecting men and
women across the globe. While the risk of kidney cancer is higher in
men than in women, there are numerous factors that determine the risk
of cancer. The two main types of kidney cancer are renal cell
carcinoma (RCC) and transitional cell carcinoma (TCC), and kidney
cancer drugs are generally administered to patients of stage four,
advanced RCC.
Browse Full Global
Kidney Cancer Drugs Market Report With Complete TOC @
http://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html
According to the
American Cancer Society, in the year 2015, approximately 61,560 new
cases of kidney cancer will be registered in the United States alone,
of which 23,290 will be women and 38,270 will be men. Out of these,
around 14,080 people will die from the disease in 2015, of which
5,010 will be women and 9,070 will be men.
The U.S. National
Cancer Institute states that kidney cancer is more common among
American Indian, African American, and Alaska Native populations.
This makes North America a rather large and lucrative market for
kidney cancer drugs.
Votrient: Most
promising commercially available kidney cancer drug
There are a number
of kidney cancer drugs that are prescribed, used, and commercially
available today. Some of the major brands are Votrient (Pazopanib),
Inlyta (Axitinib), Proleukin (Aldesleukin), Afinitor (Everolimus),
Sutent (Sunitinib), Nexavar (Sorafenib), Torisel (Temsirolimus), and
Avastin (Bevacizumab).
Of these, Sutent
(Sunitinib) dominated the kidney cancer drugs market in 2013,
accounting for 30% of the revenue share. Often considered to be the
first line of treatment for renal cell carcinoma (RCC), Sutent is one
of the most studied kidney cancer drugs for multiple indications.
However, owing to its relatively high price, this drug is expected to
register a rather meager growth rate of 1.1% from 2012 to 2016 and
2.1% from 2016 to 2020.
Votrient
(Pazopanib), on the other hand, is projected to be the most promising
kidney cancer drug during the forecast period and will witness the
strongest growth between 2012 and 2020. According to a report by
Transparency Market Research (TMR), Votrient is estimated to grow at
an outstanding CAGR of 41.7% from 2012 to 2016, and 8.9% from 2016 to
2020.
U.S. largest
pharmaceutical market in the world
The global kidney
cancer drugs market is divided into four key geographic regions:
North America, Europe, Asia-Pacific, and Rest of the World. The
growing prevalence of kidney cancer makes North America the leading
market for kidney cancer drugs; revenue-wise, this region held more
than 45% of the total share in 2013. Split into Canada and the United
States, the North America market is driven by a growing patient pool,
commercial availability of leading drugs for the treatment of kidney
cancer, a strong healthcare insurance base, and impressive healthcare
systems customized for the pharmaceutical sector. The U.S. accounted
for 90% of the North America kidney cancer drugs market.
The APAC region has
also proved to be a lucrative market for kidney cancer drugs owing to
a rising geriatric population, growing prevalence of kidney cancer,
and economic recovery and growth in countries such as China, Japan,
Australia, and New Zealand. Registering a 6% growth rate, the
Asia-Pacific market for kidney cancer drugs is anticipated to be the
fastest growing regional segment during the forecast period.
Market to register
healthy growth rate owing to intense competition
The
recently-published TMR report has indicated that the market for
kidney cancer drugs is characterized by strong competition among
industry participants. With the global market being immensely
consolidated, there are only a handful of established pharmaceutical
companies who dominate the kidney cancer drugs market. Some of the
principal players operating in the market are GlaxoSmithKline, plc,
F. Hoffmann-La Roche, Ltd., Pfizer, Inc., Bayer AG, and Novartis AG.
Among these, Pfizer was the largest maker of kidney cancer drugs in
the world and held more than 40% of the total market share in 2013.
The report states
that this concentration of power in the hands of a few contributes to
the growth of the kidney cancer drugs market. In 2013, the global
market was valued at US$2.6 billion and this is estimated to reach
US$4.5 billion by 2020, expanding at a compound annual growth rate of
6.6% till 2020.
Request a Brochure
of this Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=537
About Us
Transparency Market
Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive
blend of quantitative forecasting and trend analysis provides
forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use
proprietary data sources and various tools and techniques to gather
and analyze information.
TMR’s data
repository is continuously updated and revised by a team of research
experts so that it always reflects the latest trends and information.
With extensive research and analysis capabilities, Transparency
Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for
business reports.
Contact
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll
Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
http://www.transparencymarketresearch.com
No comments:
Post a Comment